Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Molecules › HDM1005

HDM1005

GIP/GLP-1 · s.c. · Huadong Medicine

Data cut 12 November 2026 · page built 16 November 2026 · 3 trial arms · 2 trials with results · 5 registered trials · see on the pipeline board

Summary

Also known as
Huadong
Mechanism
GIP/GLP-1
Route
s.c.
Company
Huadong Medicine
Highest development stage
phase 3
Status (as of data cut)
Phase 3 in China (obesity; T2D; head-to-head vs mazdutide in T2D) since Oct 2025; phase 2 T2D (20 wk) at EASD 2026: HbA1c up to −2.57 % verify
Next milestone
Phase 3 obesity results (primary completion Sep 2026)

Sources for the status

Indications: regulatory and evidence status

IndicationCodeStatusEvidence
Obesity2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
T2D2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
CV outcomes0 no data
CKD0 no data
HFpEF0 no data
MASH0 no data
Sleep apnoea2 phase 3 ongoingPhase 3 registered on ClinicalTrials.gov
Knee OA0 no data
Alzheimer's0 no data

4 = approved / in a label (FDA, EMA or NMPA), 3 = positive phase 3, 2 = phase 3 ongoing or completed without public results, 1 = phase 2 or signal only, 0 = no data, −1 = negative phase 3/4. L = label, P = PubMed, T = registry.

Trial arms: weight, HbA1c and tolerability

TrialArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
China Phase II (obesity, non-diabetic)2.0 mgobesity china22243——−13.3 % vs −2.5 %
estimand not specified
———————press release
China Phase II (obesity, non-diabetic)4.0 mgobesity china22243——−13.3 % vs −2.5 %
estimand not specified
———————press release
HDM1005 phase 2 (T2D)HDM1005 3.0 mgt2d china20220−5.9 % vs −0.2 %
Δ −5.7 pp
—−2.6 vs −0.6——————verified

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (4)
  • HDM1005 3.0 mg · weight_eff · Abstract, Results
    Dose-dependent body weight reductions were observed (LSM percentage change: -2.53%, -5.10%, -5.45%, -5.89% vs - 0.17% for placebo)
  • HDM1005 3.0 mg · hba1c · Abstract, Results
    the least squares mean (LSM) changes in HbA1c were -1.95%, -2.40%, -2.45%, and -2.57% for HDM1005 0.5, 1.0, 2.0, and 3.0 mg groups
  • 2.0 mg · weight_unsp · secondary
    2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%
  • 4.0 mg · weight_unsp · secondary
    2.0mg剂量组体重较基线降幅达13.31%,4.0mg组达13.28%,显著优于安慰剂组的2.46%

Registered trials (5)

From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.

TrialIndicationPhaseStatusStart → primary completionnResultRegistry
NCT07794397
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Receiving Positive Airway Pressure (PAP) Therapy
Sleep apnoeaPhase 3not yet recruiting2026-09 → 2028-09200not yet recruitingNCT07794397
NCT07787260
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of HDM1005 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Not Receiving Positive Airway Pressure (PAP) Therapy
Sleep apnoeaPhase 3not yet recruiting2026-08 → 2028-03200not yet recruitingNCT07787260
NCT07417306
A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor
T2DPhase 3not yet recruiting2026-03 → 2027-08912not yet recruitingNCT07417306
NCT07394114
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
T2DPhase 3recruiting2026-02 → 2027-08240recruitingNCT07394114
NCT07279194 · China
Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes
ObesityPhase 3recruiting2025-10 → 2026-09825recruitingNCT07279194

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: HDM1005. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/hdm1005/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.